Application of isoflurane, a volatile anesthetic, after brain ischemia can reduce ischemic brain injury in rodents (isoflurane postconditioning). This study is designed to determine whether isoflurane postconditioning improves long-term neurological outcome after focal brain ischemia and whether this protection is mediated by attenuating neuroinflammation. Adult male Sprague-Dawley rats were subjected to a 90-min middle cerebral arterial occlusion (MCAO). Isoflurane postconditioning was performed by exposing rats to 2% isoflurane for 60 min immediately after the MCAO. Isoflurane postconditioning reduced brain infarct volumes, apoptotic cells in the ischemic penumbral brain tissues and neurological deficits of rats at 4 weeks after the MCAO. Isoflurane postconditioning reduced brain ischemia/reperfusion-induced nuclear transcription factor (NF)-κB (NF-κB) activation as well as interleukin 1β (IL-1β) and interleukin-6 production in the ischemic penumbral brain tissues at 24 h after the MCAO. IL-1β deficient mice had smaller brain infarct volumes and better neurological functions than wild-type mice at 24 h after a 90-min focal brain ischemia. Isoflurane posttreatment failed to induce neuroprotection in the IL-1β deficient mice. Our results suggest that isoflurane postconditioning improved long-term neurological outcome after transient focal brain ischemia. This protection may be mediated by inhibiting NF-κB activation and the production of the proinflammatory cytokine IL-1β.
Introduction
Ischemic brain injury is the underlying pathophysiology for common human diseases, such as stroke and brain trauma. However, up till now, clinically effective and safe methods for reducing ischemic brain injury have not been established.
Postconditioning is a promising approach to reduce ischemic cell injury. The concept "ischemic postconditioning" was introduced in the literature in 2003 to describe a phenomenon in which short episodes of ischemia during the early phase of reperfusion after a prolonged ischemia in the heart reduced cardiac infarct size (Zhao et al., 2003) . Ischemic postconditioning-induced neuroprotection was shown for the first time in 2006 (Burda et al., 2006 Danielisova et al., 2006; Zhao et al., 2006) . However, it may be difficult to apply ischemic postconditioning in clinical practice because well-controlled, short episodes of brain ischemia are almost impossible to perform. We have shown that isoflurane application during reperfusion also reduces ischemic brain injury in rats (Lee et al., 2008) . Isoflurane is a volatile anesthetic and has been used in clinical practice for 3 decades. The isoflurane postconditioning-induced neuroprotection requires the application of isoflurane within 2 h after the onset of simulated reperfusion in human neuron-like cell cultures (Lin et al., 2011) . If this neuroprotection is confirmed in humans, it may be particularly applicable to patients during cardiovascular surgery and use of tissue plasminogen activator for ischemic stroke because the time of brain reperfusion can be predicated accurately in these patients.
Very little is known about the mechanisms for isoflurane postconditioning effects in the brain. It is known that brain ischemia and reperfusion induce neuroinflammation that can activate intracellular signaling pathways to cause cell death or injury (Huang et al., 2006; Iadecola and Anrather, 2011; Lakhan et al., 2009; Lipton, 1999) . Isoflurane has been shown to inhibit the activation of nuclear transcription factor (NF)-κB (NF-κB) by proinflammatory initiators, such as lipopolysaccharide (de Rossi et al., 2004) . NF-κB activation is a critical step to induce cytokine production (Giacomini et al., 2011; Liu et al., 1999) . Thus, we hypothesize that isoflurane postconditioning-induced neuroprotection involves attenuation of ischemia/reperfusion-induced Neurobiology of Disease 54 (2013) 216-224 Abbreviations: Fr1, frontal brain cortex area 1; IL-1β, interleukin 1β; MCAO, middle cerebral arterial occlusion; NF-κB, nuclear transcription factor-κB; PDTC, pyrrolidine dithiocarbamate; SpO 2 , pulse oximeter oxygen saturation; TUNEL, terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick-end labeling.
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